A sore throat is a common complaint, especially during cold and flu season, but not all sore throats are the same. Some are caused by viruses and will improve on their own, while others are caused by ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. McKesson (NYSE:MCK) announced that long-serving CFO Britt Vitalone will retire, with Kenny ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Recent quarterly results from McKesson (MCK), with revenue and operating profit ...

Summary statistics are from the Centers for Disease Control and Prevention Active Bacterial Core Surveillance reports 1-3 except for data on pregnant persons (from Phares et al. 4). Group B ...

Growing research suggests the bacteria left behind by the common childhood infection may trick the immune system into attacking both the invader and the body's own cells. Colored scanning electron ...

IRVING, Texas (AP) — IRVING, Texas (AP) — McKesson Corp. (MCK) on Wednesday reported fiscal third-quarter earnings of $1.19 billion. On a per-share basis, the Irving, Texas-based company said it had ...

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, ...

Strep throat is a common throat infection that often causes a sore throat, fever and trouble swallowing. It tends to come on quickly and may feel worse than a typical cold. While strep throat is most ...

McKesson (MCK) is one of the three major pharmaceutical drug distribution companies in the United States. It, along with Cardinal Health (CAH) and Cencora (COR), has a dominant position in the market ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...

McKesson Corporation is rated 'Buy' due to its transformation into a higher-growth, higher-margin healthcare services platform focused on Oncology & Multispecialty and Prescription Technology ...